Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi(Georgetown University), Victor Ankoma‐Sey, W Knapple(Arkansas Department of Agriculture), Aldo J. Montaño‐Loza(University of Alberta), Manal F. Abdelmalek(Mayo Clinic), Mary E. Rinella(University of Chicago), Leigh MacConell(Intercept Pharmaceuticals (United States)), Vlad Ratziu(Sorbonne Université), Michael Allison(Cambridge University Hospitals NHS Foundation Trust), Reshma Shringarpure(Intercept Pharmaceuticals (United States)), G. Mazzella(University of Bologna), Zachary Goodman(Inova Fairfax Hospital), Helena Cortez‐Pinto(University of Lisbon), Isabel Graupera(Hospital Clínic de Barcelona), Raúl J. Andrade(Hospital Clínico Universitario Virgen de la Victoria), Aftab Ala(Al-Ahliyya Amman University), Pierre Bédossa(Régie Autonome des Transports Parisiens (France)), Elisabetta Bugianesi(University of Turin), Philip N. Newsome(King's College London), David E. Shapiro(Intercept Pharmaceuticals (United States)), Andreas Geier(Swiss Integrative Center for Human Health), Rohit Loomba(University of California San Diego), Agustı́n Albillos(Universidad de Alcalá), Muhammad Y. Sheikh, Quentin M. Anstee(Newcastle upon Tyne Hospital), M. Angélico, Jérôme Boursier(Michael E. DeBakey VA Medical Center), Jason Campagna(Intercept Pharmaceuticals (United States)), William Alazawi(Queen Mary University of London), Gary A. Abrams, Luna Zaru(Intercept Pharmaceuticals (United States)), Arun J. Sanyal(Virginia Commonwealth University), Pietro Andreoné, Eric Lawitz(The University of Texas at San Antonio Health Science Center), Aijaz Ahmed(Stanford University), Guruprasad P. Aithal(NIHR Nottingham Digestive Diseases Biomedical Research Unit), Susanne Beckebaum(Essen University Hospital), David Sheridan(University Hospitals Plymouth NHS Trust), Kris V. Kowdley(Liver Institute Northwest), Stephen A. Harrison(Pinnacle Clinical Research), Jean‐François Dufour(Universidad Iberoamericana), Sfa Al-Shamma, David Orr(Auckland City Hospital), James F. Trotter(Baylor Scott & White Health), Philippe Mathurin(Centre Hospitalier Universitaire de Lille), Humberto Aguilar, Elmar Aigner, Lise Lotte Gluud(University of Copenhagen), Antonio Olveira(Hospital Universitario La Paz)
Cited by 1,211
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k